Jonathan Spicer

27PUBLICATIONS
227CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersGene expression (incl. microarray and other genome-wide approaches)Oncology and carcinogenesis not elsewhere classifiedSolid tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (27)

|Oct 27, 2026
Neoadjuvant durvalumab plus chemotherapy in resectable or borderline resectable non-small-cell lung cancer: the phase 2 MDT-BRIDGE trial.

|Oct 25, 2026
ctDNA clearance and outcomes for resectable lung cancer from NeoCOAST-2.

|Aug 12, 2026
Biomarkers of nivolumab benefit in resectable non-small cell lung cancer.

|Jan 08, 2026
Clinical outcomes with perioperative nivolumab by nodal status in patients with stage III resectable NSCLC: phase 3 CheckMate 77T exploratory analysis.

Mariano Provencio, Mark M Awad, Jonathan D Spicer

|Dec 03, 2025
Architecture of the neutrophil compartment.

Daniela Cerezo-Wallis, Andrea Rubio-Ponce, Mathis Richter

|May 31, 2025
Perioperative durvalumab plus chemotherapy plus new agents for resectable non-small-cell lung cancer: the platform phase 2 NeoCOAST-2 trial.

Tina Cascone, Laura Bonanno, Florian Guisier

Pageof 5

Frequent Collaborators

7 joint publications

Patrick M Forde

5 joint publications

Tina Cascone

5 joint publications

Mariano Provencio Pulla

5 joint publications

Logan A Walsh